Latest On Enveric Biosciences Inc (AMRH):
About Enveric Biosciences Inc (AMRH):
Ameri Holdings, Inc., through its subsidiaries, provides SAP cloud, digital, and enterprise services worldwide. The company offers cloud services, including public, private, and hybrid cloud services, as well as SAP S/4 HANA, SAP SuccessFactors, and SAP Hybris cloud migration; and cloud automation solutions. It also provides digital services, such as Simple Advance Planning and Optimization mobile solution, a mobile application that offers sales professionals with real-time collaboration capabilities and customer data on their mobile devices; SAP IBP mobile app, which enables the real-time management and analysis of sales and operations planning related data from mobile devices; and robotic process automation that leverages the capability of artificially intelligent software agents for business process automation, as well as for reporting and analysis, and deliver insights into business functions by translating large data into structured reports. In addition, the company's digital services comprise automating disparate and redundant data entry tasks by configuring software robots to integrate with existing software systems; and automating standard back office operations. Additionally, it designs, implements, and manages business intelligence and analytics solutions; generates instant financial reports and analytics of customer, product, and cost information; solutions for metadata repository, master data management, and data quality; and other enterprise services, such as consulting services for global and regional SAP implementations, as well as SAP/ information technology (IT) solution advisory and architectural, project management, IT/ enterprise resource planning (ERP) strategy, and vendor selection services. The company also offers data warehousing and other ERP services. Ameri Holdings, Inc. is headquartered in Suwanee, Georgia.
General
- Name Enveric Biosciences Inc
- Symbol AMRH
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorTechnology
- IndustryInformation Technology Services
- Full Time Employees 397
- Last Split Factor1:4
- Last Split Date2020-12-31
- Fiscal Year EndDecember
- IPO Date2015-06-24
- Gic SectorInformation Technology
- Gic GroupSoftware & Services
- Gic IndustryIT Services
- Gic SubIndustryIT Consulting & Other Services
- Web URLhttp://www.ameri100.com
Valuation
- Price/Sales (Trailing 12 Mt.) 0.11
- Price/Book (Most Recent Quarter) 0.57
- Enterprise Value Revenue 0.35
Financials
- Most Recent Quarter 2020-09-30
- Profit Margin -19%
- Operating Margin -17%
- Return on Assets -13%
- Return on Equity -52%
- Revenue 35.41 million
- Earnings Per Share -$0.50
- Revenue Per Share $9.42
- Gross Profit 8.15 million
- Quarterly Earnings Growth -7.3%
Highlights
- Market Capitalization 2.77 million
- EBITDA -2790883
- Analyst Target Price $0.5
- Book Value Per Share $2.30
Share Statistics
- Shares Outstanding 7.49 million
- Shares Float 6.55 million
- % Held by Insiders 918%
- % Held by Institutions 0.55%
- Shares Short 49909
- Shares Short Prior Month 123187
- Short Ratio 0.04
Technicals
- Beta 5.73
- 52 Week High $9.96
- 52 Week Low $2.51
- 50 Day Moving Average 4.89
- 200 Day Moving Average 5.53
Dividends
- Dividend Date N/A
- ExDividend Date 2008-04-23
- Dividend Yield 0%
Enveric Biosciences Inc (AMRH) Dividend Calendar:
Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
---|
Enveric Biosciences Inc (AMRH) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
---|---|---|---|---|---|
2020-09-30 | 2020-11-17 | $N/A | -$0.20 | ||
2020-06-30 | 2020-09-30 | $N/A | -$0.20 | ||
2020-03-31 | 2020-06-30 | $9.6 million | -$0.48 | ||
2019-12-31 | 2020-03-31 | $9.06 million | -$0.60 | $0.00 | |
2019-09-30 | 2019-12-31 | $9.15 million | -$1.05 | ||
2019-06-30 | 2019-09-30 | $11.02 million | -$0.03 | ||
2019-03-31 | 2019-06-30 | $10.69 million | -$0.67 | ||
2018-12-31 | 2019-03-31 | $10.28 million | -$1.09 | -$1.00 | -9% |
2018-09-30 | 2018-11-14 | $10.58 million | -$3.62 | -$1.25 | -189.4% |
2018-06-30 | 2018-08-14 | $11.08 million | -$1.75 | -$2.00 | 12.5% |
2018-03-31 | 2018-04-02 | $11.06 million | -$2.50 | -$6.00 | 58.42% |
2017-09-30 | 2017-11-13 | $12.53 million | -$7.75 | ||
2017-06-30 | 2017-08-14 | $12.27 million | -$6.48 | ||
2017-03-31 | 2017-05-12 | $12.34 million | -$2.16 | ||
2016-12-31 | 2017-03-31 | $12.39 million | $2.34 | ||
2016-09-30 | 2016-11-14 | $10.06 million | -$3.15 | ||
2016-06-30 | 2016-08-12 | $6.69 million | -$2.35 | ||
2016-03-31 | 2016-03-31 | $7.01 million | -$2.44 | ||
2015-12-31 | 2015-12-31 | $7.58 million | -$3.69 | ||
2015-09-30 | 2015-09-30 | $4.46 million | -$0.54 | ||
2015-06-30 | 2015-06-30 | $3.93 million | $0.17 | ||
2015-03-31 | 2015-03-31 | $4.29 million | -$0.07 | ||
2014-12-31 | 2014-12-31 | -$0.31 | |||
2014-09-30 | 2014-09-30 | $N/A | -$0.09 | ||
2014-06-30 | 2014-06-30 | $N/A | -$0.34 | ||
2014-03-31 | 2014-03-31 | $N/A | -$0.23 | ||
2013-12-31 | 2013-12-31 | $0.47 | |||
2013-09-30 | 2013-09-30 | -$0.17 | |||
2013-06-30 | 2013-06-30 | -$0.14 | |||
2013-03-31 | 2013-03-31 | -$0.17 | |||
2012-12-31 | 2013-02-28 | -$0.42 | |||
2012-09-30 | 2012-11-13 | -$0.18 | |||
2012-06-30 | 2012-08-01 | -$0.15 | |||
2012-03-31 | 2012-05-03 | -$0.15 | |||
2011-12-31 | 2012-03-07 | -$0.78 | |||
2011-09-30 | 2011-11-14 | $N/A | -$0.19 | ||
2011-06-30 | 2011-08-02 | $N/A | -$0.25 | ||
2011-03-31 | 2011-05-16 | -$0.75 | |||
2010-12-31 | 2010-12-31 | -$0.92 | |||
2010-09-30 | 2010-09-30 | -$0.38 | |||
2010-06-30 | 2010-06-30 | -$0.30 | |||
2010-03-31 | 2010-03-31 | -$1.07 | |||
2009-12-31 | 2009-12-31 | -$1.27 | |||
2009-09-30 | 2009-09-30 | -$0.30 | |||
2009-06-30 | 2009-06-30 | -$0.92 | |||
2009-03-31 | 2009-03-31 | -$1.47 | |||
2008-12-31 | 2008-12-31 | -$2.37 | |||
2008-09-30 | 2008-09-30 | -$0.52 | |||
2008-06-30 | 2008-08-13 | -$2.47 | |||
2008-03-31 | 2008-05-17 | -$4.36 | |||
2007-12-31 | 2007-12-31 | -$44.03 | |||
2007-09-30 | 2007-09-30 | $31.99 | |||
2007-06-30 | 2007-06-30 | $10.76 | |||
2007-03-31 | 2007-03-31 | $21.10 | |||
2006-12-31 | 2006-12-31 | -$4.92 | |||
2006-09-30 | 2006-09-30 | -$5.58 | |||
2006-06-30 | 2006-06-30 | -$5.69 | |||
2006-03-31 | 2006-03-31 | -$15.65 | |||
2005-12-31 | 2005-12-31 | -$17.40 | |||
2005-09-30 | 2005-09-30 | $3.43 | |||
2005-06-30 | 2005-06-30 | $5.40 | |||
2005-03-31 | 2005-03-31 | $0.94 | |||
2004-12-31 | 2004-12-31 | $15.95 | |||
2004-09-30 | 2004-09-30 | -$7.55 | |||
2004-06-30 | 2004-06-30 | -$11.55 | |||
2004-03-31 | 2004-03-31 | -$11.59 | |||
2003-12-31 | 2003-12-31 | -$9.50 | |||
2003-09-30 | 2003-09-30 | -$9.89 | |||
2003-06-30 | 2003-06-30 | -$19.73 | |||
2003-03-31 | 2003-03-31 | -$6.91 | |||
2002-09-30 | 2002-09-30 | $1.03 | |||
2002-06-30 | 2002-06-30 | $0.28 | |||
2002-03-31 | 2002-03-31 | $1.98 | |||
2001-09-30 | 2001-09-30 | -$16.28 | |||
2001-06-30 | 2001-06-30 | -$9.06 | |||
2001-03-31 | 2001-03-31 | $0.52 | |||
2000-09-30 | 2000-09-30 | $9.79 | |||
2000-06-30 | 2000-06-30 | $10.57 | |||
2000-03-31 | 2000-03-31 | $16.19 | |||
1999-09-30 | 1999-09-30 | $4.13 | |||
1999-06-30 | 1999-06-30 | $1.75 | |||
1999-03-31 | 1999-03-31 | -$18.91 | |||
1998-09-30 | 1998-09-30 | -$224.28 | |||
1998-06-30 | 1998-06-30 | -$224.31 | |||
1998-03-31 | 1998-03-31 | -$189.15 |
Enveric Biosciences Inc (AMRH) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
Date |
---|
Research Development |
Income Before Tax |
Selling General Administrative |
Gross Profit |
Ebit |
Operating Income |
Income Tax Expense |
Total Revenue |
Cost of Revenue |
Total Other Income Expense Net |
Net Income From Continuing Operations |
Net Income Applicable to Common Shares |
Cash Flow:
Date |
---|
Investments |
Change to Liabilities |
Total Cash Flow from Investing Activities |
Net Borrowings |
Total Cash Flow from Financial Activities |
Change to Operating Activities |
Change in Cash |
Total Cash from Operating Activities |
Depreciation |
Other Cash Flow from Investing Activities |
Change to Inventory |
Change to Account Receivables |
Other Cash Flow from Financing Activities |
Change to Net Income |
Capital Expenditures |
Balance Sheet:
Date |
---|
Total Liabailities |
Total Stockholder Equity |
Other Current Liabilities |
Total Assets |
Common Stock |
Other Current Assets |
Retained Earnings |
Other Liabilities |
Other Assets |
Cash |
Total Current Liabilities |
Other Stockholder Equity |
Property, Plant & Equipment |
Total Current Assets |
Long Term Investments |
Net Tangible Assets |
Short Term Investments |
Long Term Debt |
Inventory |
Accounts Payable |
Enveric Biosciences Inc (AMRH) Chart:
Enveric Biosciences Inc (AMRH) News:
Below you will find a list of latest news for Enveric Biosciences Inc (AMRH) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Enveric Biosciences Inc (AMRH) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
---|
Enveric Biosciences Inc (AMRH) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
Date | Form Type | Form Name | Link |
---|---|---|---|
2020-06-04 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/890821/000149315220010536/0001493152-20-010536-index.htm |
2019-08-22 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/890821/000000000019012757/0000000000-19-012757-index.htm |
2019-08-14 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/890821/000114036119014999/0001140361-19-014999-index.htm |
2019-08-23 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/890821/000114036119015538/0001140361-19-015538-index.htm |
2019-08-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/890821/000114036119015609/0001140361-19-015609-index.htm |
2019-09-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/890821/000114036119017014/0001140361-19-017014-index.htm |
2019-09-27 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/890821/000114036119017341/0001140361-19-017341-index.htm |
2019-10-30 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/890821/000114036119019435/0001140361-19-019435-index.htm |
2019-10-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/890821/000114036119019436/0001140361-19-019436-index.htm |
2019-10-31 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/890821/000114036119019466/0001140361-19-019466-index.htm |
2019-11-08 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/890821/000114036119020184/0001140361-19-020184-index.htm |
2019-11-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/890821/000114036119020187/0001140361-19-020187-index.htm |
2019-11-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/890821/000114036119020188/0001140361-19-020188-index.htm |
2019-11-12 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/890821/000114036119020291/0001140361-19-020291-index.htm |
2019-11-15 | S-3/A | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/890821/000114036119020665/0001140361-19-020665-index.htm |
2019-11-15 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/890821/000114036119020688/0001140361-19-020688-index.htm |
2019-11-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/890821/000114036119021241/0001140361-19-021241-index.htm |
2019-11-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/890821/000114036119021278/0001140361-19-021278-index.htm |
2019-11-26 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/890821/000114036119021424/0001140361-19-021424-index.htm |
2019-11-26 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/890821/000114036119021425/0001140361-19-021425-index.htm |
2019-12-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/890821/000114036119022483/0001140361-19-022483-index.htm |
2020-01-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/890821/000114036120000667/0001140361-20-000667-index.htm |
2020-01-13 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/890821/000114036120000669/0001140361-20-000669-index.htm |
2020-01-16 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/890821/000114036120000990/0001140361-20-000990-index.htm |
2020-01-21 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/890821/000114036120001153/0001140361-20-001153-index.htm |
2020-01-27 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/890821/000114036120001508/0001140361-20-001508-index.htm |
2020-02-27 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/890821/000114036120004205/0001140361-20-004205-index.htm |
2020-03-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/890821/000114036120004807/0001140361-20-004807-index.htm |
2020-03-25 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/890821/000114036120006825/0001140361-20-006825-index.htm |
2020-05-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/890821/000114036120010802/0001140361-20-010802-index.htm |
2019-09-27 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/890821/000114420419046316/0001144204-19-046316-index.htm |
2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/890821/000119312520038578/0001193125-20-038578-index.htm |
2020-05-06 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/890821/000121390020011150/0001213900-20-011150-index.htm |
2020-01-31 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/890821/000139382520000014/0001393825-20-000014-index.htm |
2020-05-28 | S-4 | Registration of securities, business combinations | https://www.sec.gov/Archives/edgar/data/890821/000149315220009947/0001493152-20-009947-index.htm |
2020-06-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/890821/000149315220010211/0001493152-20-010211-index.htm |
2020-06-02 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/890821/000149315220010390/0001493152-20-010390-index.htm |
2020-06-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/890821/000149315220010535/0001493152-20-010535-index.htm |
2020-06-04 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/890821/000149315220010536/0001493152-20-010536-index.htm |
2020-08-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/890821/000149315220014442/0001493152-20-014442-index.htm |
2020-08-04 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/890821/000149315220014566/0001493152-20-014566-index.htm |
2020-08-12 | S-4/A | Registration of securities, business combinations | https://www.sec.gov/Archives/edgar/data/890821/000149315220015374/0001493152-20-015374-index.htm |
2020-08-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/890821/000149315220015383/0001493152-20-015383-index.htm |
2020-08-12 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/890821/000149315220015385/0001493152-20-015385-index.htm |
2020-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/890821/000149315220015855/0001493152-20-015855-index.htm |
2020-09-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/890821/000149315220017593/0001493152-20-017593-index.htm |
2020-09-16 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/890821/000149315220017871/0001493152-20-017871-index.htm |
2020-09-17 | S-4/A | Registration of securities, business combinations | https://www.sec.gov/Archives/edgar/data/890821/000149315220017916/0001493152-20-017916-index.htm |
2020-10-22 | S-4/A | Registration of securities, business combinations | https://www.sec.gov/Archives/edgar/data/890821/000149315220019817/0001493152-20-019817-index.htm |
2020-11-04 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/890821/000149315220020444/0001493152-20-020444-index.htm |
2020-05-15 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/890821/000156761920010243/0001567619-20-010243-index.htm |
2019-11-19 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/890821/999999999519002607/9999999995-19-002607-index.htm |